Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives

References

• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–24.
   PubMed Web of Science ®Google Scholar
• Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191–7.
   PubMed Web of Science ®Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65–70.
   PubMedGoogle Scholar
• Matsui T, Omura K, Kawakami K, Morita S, Sakamoto J. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol Rep 2006;16:1111–15.
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 2007;17:637–45.
   PubMed Web of Science ®Google Scholar
• Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007;17:325–8.
   PubMed Web of Science ®Google Scholar
• Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002;17:46–9.
   PubMed Web of Science ®Google Scholar
• Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008;8:256–67.
   PubMed Web of Science ®Google Scholar
• Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–05. J Clin Oncol 28:2556–64.
   PubMedGoogle Scholar
• Martinez-Balibrea E, Abad A, Martinez-Cardus A, Gines A, Valladares M, Navarro M, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103:581–9.
   PubMed Web of Science ®Google Scholar
• Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004;10:5880–8.
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365–9.
   PubMed Web of Science ®Google Scholar
• Hitre E, Budai B, Adleff V, Czegledi F, Horvath Z, Gyergyay F, Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723–30.
   PubMed Web of Science ®Google Scholar
• Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Br J Cancer 2008;99:716–21.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;112:733–7.
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008;8:278–88.
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344–54.
   PubMed Web of Science ®Google Scholar
• Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003;9:1611–15.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69:58–66.
   PubMed Web of Science ®Google Scholar
• Castillo-Fernandez O, Santibanez M, Bauza A, Calderillo G, Castro C, Herrera R, Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res 41:430–5.
   PubMed Web of Science ®Google Scholar
• Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008;14:817–25.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Haba E, Garcia MI, Cortejoso L, Lopez-Lillo C, Barrueco N, Garcia-Alfonso P, ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 11:1715–23.
   PubMed Web of Science ®Google Scholar
• Caronia D, Martin M, Sastre J, de la Torre J, Garcia-Saenz JA, Alonso MR, A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 17:2006–13.
   PubMed Web of Science ®Google Scholar
• Ribelles N, Lopez-Siles J, Sanchez A, Gonzalez E, Sanchez MJ, Carabantes F, A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 2008;9:336–43.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li YM, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007;24:251–8.
   PubMed Web of Science ®Google Scholar
• Kim JC, Kim SY, Cho DH, Roh SA, Choi EY, Jo YK, Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers. Cancer Sci 101;1007–13.
   Google Scholar
• Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E, Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006;24:1603–11.
   PubMed Web of Science ®Google Scholar
• Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ, Garcia de Paredes ML, Gisbert JP, Roda-Navarro P, Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol 2006;28:1303–10.
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247–54.
   PubMed Web of Science ®Google Scholar
• Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21:18–25.
   PubMed Web of Science ®Google Scholar
• Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162–6.
   PubMedGoogle Scholar
• Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212–17.
   PubMed Web of Science ®Google Scholar
• Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007;25:5172–9.
   PubMed Web of Science ®Google Scholar
• Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, ERCC1 codon 118 C–>T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009;100:278–83.
   PubMed Web of Science ®Google Scholar
• Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008;14:6401–7.
   PubMed Web of Science ®Google Scholar
• Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res 708:21–7.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999;366:89–94.
   PubMed Web of Science ®Google Scholar
• Jun L, Haiping Z, Beibei Y. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 2009;139:724–8.
   PubMed Web of Science ®Google Scholar
• Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101:530–5.
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;94:936–42.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28:3227–33.
   PubMed Web of Science ®Google Scholar
• Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48:729–34.
   PubMed Web of Science ®Google Scholar
• Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol.
   Web of Science ®Google Scholar
• Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005;5:124–31.
   PubMedGoogle Scholar
• Chen J, Xie F, Chen K, Wang D, Jiang H, Li J, ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther 2009;8:1424–30.
   PubMed Web of Science ®Google Scholar
• Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11:33–41.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim NS, Park JY, Chae YS, Kim JG, Sohn SK, MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. J Cancer Res Clin Oncol 136:1135–42.
   PubMed Web of Science ®Google Scholar
• Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654–8.
   PubMed Web of Science ®Google Scholar
• Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009;100:1261–6.
   PubMed Web of Science ®Google Scholar
• Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007;72:364–70.
   PubMed Web of Science ®Google Scholar
• Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006;13:1379–85.
   Google Scholar
• Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075–9.
   PubMed Web of Science ®Google Scholar
• Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms. Jpn J Clin Oncol 41:477-82.
   PubMed Web of Science ®Google Scholar
• Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009;27:2457–65.
   PubMed Web of Science ®Google Scholar
• Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151–9.
   PubMed Web of Science ®Google Scholar
• Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008;112:1932–40.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061–8.
   PubMed Web of Science ®Google Scholar
• Rouits E, Charasson V, Petain A, Boisdron-Celle M, Delord JP, Fonck M, Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008;99:1239–45.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678–82.
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290–5.
   PubMed Web of Science ®Google Scholar
• Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 2009;54:572–80.
   PubMed Web of Science ®Google Scholar
• Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008;99:1316–21.
   PubMed Web of Science ®Google Scholar
• Romero RZ, Morales R, Garcia F, Huarriz M, Bandres E, De la Haba J, Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 2006;16:497–503.
   PubMed Web of Science ®Google Scholar
• Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J.
   Web of Science ®Google Scholar
• Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007;98:1461–7.
   PubMed Web of Science ®Google Scholar
• Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006;106:1007–16.
   PubMed Web of Science ®Google Scholar
• Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13:3269–75.
   PubMed Web of Science ®Google Scholar
• Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226–36.
   PubMed Web of Science ®Google Scholar
• Artac M, Bozcuk H, Pehlivan S, Akcan S, Pehlivan M, Sever T, The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J Cancer Res Clin Oncol 136:803–9.
   PubMed Web of Science ®Google Scholar
• Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V, Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427–34.
   PubMed Web of Science ®Google Scholar
• Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 46:1829–34.
   PubMed Web of Science ®Google Scholar
• Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci 101:793–9.
   PubMed Web of Science ®Google Scholar
• Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008;14:7884–95.
   PubMed Web of Science ®Google Scholar
• Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, Kim CW, Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 17:1200–9.
   PubMed Web of Science ®Google Scholar
• Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Cruger D, The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879–84.
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712–18.
   PubMed Web of Science ®Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122–9.
   PubMed Web of Science ®Google Scholar
• Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22:104–9.
   PubMed Web of Science ®Google Scholar
• Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 10:458–64.
   PubMed Web of Science ®Google Scholar
• Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009;69:7905–10.
   PubMed Web of Science ®Google Scholar
• Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 17:372–81.
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554–63.
   PubMed Web of Science ®Google Scholar
• Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 26:143–51.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672–8.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 921–8.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:247.
   PubMed Web of Science ®Google Scholar